Sintilimab Combined With Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Single Arm Phase II Study
Latest Information Update: 04 Nov 2021
At a glance
- Drugs Sintilimab (Primary) ; Tucidinostat (Primary)
- Indications Cutaneous T-cell lymphoma
- Focus Therapeutic Use
Most Recent Events
- 09 Mar 2020 New trial record